WO2012169735A3 - Complexe comprenant des fragments hydrosolubles de fcεri et composition le contenant pour traiter les maladies allergiques médiées par l'ige - Google Patents

Complexe comprenant des fragments hydrosolubles de fcεri et composition le contenant pour traiter les maladies allergiques médiées par l'ige Download PDF

Info

Publication number
WO2012169735A3
WO2012169735A3 PCT/KR2012/004075 KR2012004075W WO2012169735A3 WO 2012169735 A3 WO2012169735 A3 WO 2012169735A3 KR 2012004075 W KR2012004075 W KR 2012004075W WO 2012169735 A3 WO2012169735 A3 WO 2012169735A3
Authority
WO
WIPO (PCT)
Prior art keywords
fcεri
ige
complex
water
soluble fragments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2012/004075
Other languages
English (en)
Korean (ko)
Other versions
WO2012169735A2 (fr
WO2012169735A9 (fr
Inventor
박병덕
윤선주
김욱동
배종환
김민희
강현정
박은혜
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neopharm Co Ltd
Original Assignee
Neopharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neopharm Co Ltd filed Critical Neopharm Co Ltd
Priority claimed from KR1020120054613A external-priority patent/KR20120135865A/ko
Publication of WO2012169735A2 publication Critical patent/WO2012169735A2/fr
Publication of WO2012169735A3 publication Critical patent/WO2012169735A3/fr
Publication of WO2012169735A9 publication Critical patent/WO2012169735A9/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Cette invention concerne un complexe contenant des fragments hydrosolubles de FcεRI, qui est un récepteur ayant une forte affinité pour la région Fc de l'immunoglobuline E (IgE), liés à un matériau doué de biocompatibilité. Le complexe contenant des fragments hydrosolubles de FcεRI liés à un matériau doué de biocompatibilité selon cette invention inhibe le couplage de l'IgE et du FcεRI, qui est un récepteur de l'IgE, de façon à supprimer la sécrétion d'une cytokine allergique. Le complexe selon l'invention a, par conséquent, pour effet de traiter et de prévenir les maladies allergiques.
PCT/KR2012/004075 2011-06-07 2012-05-23 Complexe comprenant des fragments hydrosolubles de fcεri et composition le contenant pour traiter les maladies allergiques médiées par l'ige Ceased WO2012169735A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2011-0054805 2011-06-07
KR20110054805 2011-06-07
KR10-2012-0054613 2012-05-23
KR1020120054613A KR20120135865A (ko) 2011-06-07 2012-05-23 ＦｃεＲＩ의 수용성 단편을 포함하는 복합체 및 이를 포함하는 ＩｇＥ 매개 알레르기성 질환 치료용 조성물

Publications (3)

Publication Number Publication Date
WO2012169735A2 WO2012169735A2 (fr) 2012-12-13
WO2012169735A3 true WO2012169735A3 (fr) 2013-03-07
WO2012169735A9 WO2012169735A9 (fr) 2013-05-02

Family

ID=47296555

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/004075 Ceased WO2012169735A2 (fr) 2011-06-07 2012-05-23 Complexe comprenant des fragments hydrosolubles de fcεri et composition le contenant pour traiter les maladies allergiques médiées par l'ige

Country Status (1)

Country Link
WO (1) WO2012169735A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI691512B (zh) 2015-02-20 2020-04-21 日商橘生藥品工業股份有限公司 Ｆｃ融合高親和性ＩｇＥ受體α鏈
SG11202005863TA (en) * 2018-01-12 2020-07-29 Gi Innovation Inc Composition comprising probiotics and polypeptide having binding affinity for ige and use thereof
KR102561135B1 (ko) 2019-07-08 2023-07-31 (주)지아이이노베이션 IgE Fc 수용체의 알파 서브유닛의 세포외 도메인을 포함하는 시알산 함량이 높은 폴리펩티드 이량체 및 이를 포함하는 약학적 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100502879B1 (ko) * 1996-07-26 2005-07-25 노파르티스 아게 ＩｇＥ­결합 도메인 및 ＨＳＡ 성분을 포함하는 융합 폴리펩티드, 그의 진단 및 치료 용도
KR100464699B1 (ko) * 1995-12-18 2005-07-28 이섬 리서치 디벨러프먼트 컴파니 오브 더 히브루 유니버시티 오브 예루살렘 알레르기반응의표적치료용인키메라단백질,이의제조방법및이를포함하는약제조성물
US20050170451A1 (en) * 2001-07-19 2005-08-04 Judicial Foundation The Chemo-Sero-Therapeutic Res Human type antihuman ige receptor antibody and fragment

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100464699B1 (ko) * 1995-12-18 2005-07-28 이섬 리서치 디벨러프먼트 컴파니 오브 더 히브루 유니버시티 오브 예루살렘 알레르기반응의표적치료용인키메라단백질,이의제조방법및이를포함하는약제조성물
KR100502879B1 (ko) * 1996-07-26 2005-07-25 노파르티스 아게 ＩｇＥ­결합 도메인 및 ＨＳＡ 성분을 포함하는 융합 폴리펩티드, 그의 진단 및 치료 용도
US20050170451A1 (en) * 2001-07-19 2005-08-04 Judicial Foundation The Chemo-Sero-Therapeutic Res Human type antihuman ige receptor antibody and fragment

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
STEPHEN J. DEMAREST ET AL.: "An Intermediate pH Unfolding Transition Abrogates the Ability of IgE to IOnteract with Its High Affinity Receptor FcepcilronRlalpha", JBC, vol. 281, no. 41, 2006, pages 30755 - 30767 *

Also Published As

Publication number Publication date
WO2012169735A2 (fr) 2012-12-13
WO2012169735A9 (fr) 2013-05-02

Similar Documents

Publication Publication Date Title
MY162511A (en) Engineered anti-tslp antibody
WO2010136311A3 (fr) Compositions et procédés de ciblage de la protéine c3b de complément par des anticorps
PH12013500564A1 (en) Anti-cd48 antibodies and uses thereof
HK1211599A1 (en) Il-6 antagonists and uses thereof
WO2011113019A3 (fr) Protéines ctla4 et leurs utilisations
HK1250238A1 (zh) 抗angptl8抗体及其用途
MX348637B (es) Anticuerpos y composiciones anti-her3.
MX2010008688A (es) Anticuerpos anti-receptor de linfopoyetina estromal timica procesados por ingenieria.
WO2013151668A3 (fr) Polynucléotides modifiés destinés à la production de protéines sécrétées
HK1206612A1 (en) Modified polynucleotides for the production of secreted proteins
WO2012149356A3 (fr) Anticorps anti-cd40 et leurs procédés d'utilisation
MY160608A (en) APTAMERS TO ß-NGF AND THEIR USE IN TREATING ß-NGF MEDIATED DISEASES AND DISORDERS
WO2013022991A3 (fr) Méthodes et compositions associées à p62 pour le traitement et la prophylaxie du cancer
JO3532B1 (ar) الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
WO2011044563A3 (fr) Compositions de cytokines de la famille il-17 et utilisations
WO2010021874A3 (fr) Anticorps anti-il-13 modifiés, compositions, procédés et utilisations
MX2013007067A (es) Anticuerpos anti-il-18 y sus usos.
WO2012017324A3 (fr) Composition pharmaceutique à combinaison et méthodes de traitement de maladies ou états associés à des maladies neurodégénératives
MX362089B (es) Nanopartículas que comprenden materiales metálicos y óxido de hafnio, preparación y usos de los mismos.
WO2012138768A3 (fr) Anticorps anti-cd154 ayant une liaison détériorée au fcr et/ou des propriétés de liaison au complément détériorée et leur utilisation dans des thérapies immunologiques
GEP201706789B (en) Antibody formulations and uses thereof
PH12014501410A1 (en) Compositions and methods for antibodies targeting factor p
DK2417158T4 (da) Dkk-1-antistoffer
IN2012DN01984A (fr)
DK2714888T3 (da) Rekombinant gær

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12797149

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12797149

Country of ref document: EP

Kind code of ref document: A2